Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. (Q36938818)
Jump to navigation
Jump to search
scientific article published on 13 April 2015
Language | Label | Description | Also known as |
---|---|---|---|
English | Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. |
scientific article published on 13 April 2015 |
Statements
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (English)
Melissa L Johnson
Helena A Yu
Eric M Hart
Bing Bing Weitner
Alfred W Rademaker
Jyoti D Patel